Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases

Open-label Phase 2 trial evaluating ebribafusp for the treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathyInitial data is ...
Yahoo Finance

Complement 3 Glomerulopathy Market Poised for Phenomenal Expansion at a CAGR of 37.2% During the Forecast Period (2025–2034) Owing to the Launch of Promising Therapies ...

In 2024, the diagnosed prevalent population of C3 glomerulopathy in the 7MM was approximately 5,800. This number is expected to rise through 2034, driven by advances in complement biology, improved ...
Healthline

An Overview of Complement 3 Glomerulopathy (C3G)

Complement 3 glomerulopathy (C3G) is a rare kidney disease that affects your body’s innate immune system (complement system). Complement 3 glomerulopathy (C3G) is a kidney disease that’s caused by ...
FiercePharma

Amyndas’ lead candidate AMY-101 receives orphan drug status from the FDA and the EMA for the treatment of C3 glomerulopathy

Amyndas Pharmaceuticals SA, which is committed to developing innovative therapeutics to treat complement-mediated disorders, announced today that its lead candidate, the C3 complement inhibitor ...

Complement 3 Glomerulopathy (C3G) Market Analysis Report 2026-2036 | Complement 3 Glomerulopathy Market Forecast to Reach Approximately $1 Billion by 2036 as Targeted Therapies ...

Assessment of the Treatment Landscape, Epidemiology Insights, C3G Pipeline, Competitive Landscape, Market Drivers, Unmet Needs, Market Access, Pricing, and ReimbursementDublin, Sept. 08, 2026 (GLOBE ...
Business Wire

Arrowhead Announces Interim Results from Ongoing Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced interim results from Part 1 of AROC3-1001, an ongoing Phase 1/2 clinical study of ARO-C3, the company’s ...
The New England Journal of Medicine

Breakthrough Hemolysis in PNH with Proximal or Terminal Complement Inhibition

The figure focuses on complement activation by means of the alternative pathway because it is the one responsible for hemolysis in PNH. The lightning bolt symbolizes the spontaneous hydrolytic ...